European Medicines Agency recommends to extend the indications for ipilimumab

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product ipilimumab (Yervoy). The CHMP adopted a change to the indication, extending the use of the medicine to previously untreated patients. The change adopted is as follows: “YERVOY is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults." Read more here.